Risankizumab-rzaa (Skyrizi) (CPB 1009, reviewed 2026-10-14)
Summary
Aetna's Clinical Policy Bulletin 1009 covers risankizumab-rzaa (Skyrizi) for commercial medical plans, and precertification is required of all Aetna participating providers and members in applicable plan designs for intravenous risankizumab-rzaa. Aetna considers it medically necessary for moderate to severe plaque psoriasis in members 6 years of age or older who have previously received a biologic or targeted synthetic drug, or when crucial body areas, at least 10% of body surface area, or at least 3% of body surface area with an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin is affected. It also covers active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis, and Aetna considers concomitant use with another biologic or targeted synthetic drug for the same indication experimental, investigational, or unproven.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.